Association between decreased serum albuminwith risk of venous thromboembolism and mortality in cancer patients

Oncologist

Volumn 21, Issue 2, 2016, Pages 252-257

  Königsbrügge, Oliver ^a,b   Posch, Florian ^a,b   Riedl, Julia ^a,b   Reitter, Eva Maria ^a,b   Zielinski, Christoph ^a,b   Pabinger, Ingrid ^a,b   Ay, Cihan ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Austrian Breast and Colorectal Cancer Study Group   (Austria)

Author keywords

Cancer; Mortality; Risk; Serum albumin; Venous thromboembolism

Indexed keywords

CHOLINESTERASE; HUMAN SERUM ALBUMIN; SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CANCER PATIENT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM; BLOOD; INFLAMMATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SERUM ALBUMIN; VENOUS THROMBOEMBOLISM;

EID: 84957554807     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0284     Document Type: Article

References (20)

1. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–4907.
2. Folsom AR, Lutsey PL, Heckbert SR et al. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010;104:100–104.
3. Shah MA, Capanu M, Soff G et al. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010;8: 1702–1709.
4. Mahmoodi BK, Gansevoort RT, Næss IA et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: Pooled analysis of five prospective general population cohorts. Circulation 2012;126:1964–1971.
5. Olson NC, Cushman M, Lutsey PL et al. Inflammation markers and incident venous thromboembolism: The REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost 2014;12:1993–2001.
6. Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol 2012;29: 2005–2009.
7. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: The Glasgow Prognostic Score. Cancer Treat Rev 2014;40:685–691.
8. Proctor MJ, McMillan DC, Horgan PG et al. Systemic inflammation predicts all-cause mortality: A Glasgow inflammation outcome study. PLoS One 2015;10:e0116206.
9. Seebacher V, Grimm C, Reinthaller A et al. The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2013;171: 101–106.
10. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
11. Fine J, Gray R.Aproportional hazardsmodelfor the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
12. Lyman GH, Bohlke K, Khorana AA et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015;33:654–656.
13. Ulas A, Turkoz FP, Silay K et al. A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One 2014;9: e114471.
14. Du X-J, Tang L-L, Mao Y-P et al. The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One 2014;9:e94473.
15. Yi JH, Lee J, Park SH et al. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 2011;80:175–180.
16. Ayuk F, Bussmann L, Zabelina T et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol 2014;93:855–861.
17. Pant S, Martin LK, Geyer S et al. Baseline serum albumin is a predictive biomarker for patients with advancedpancreaticcancertreatedwithbevacizumab: Apooledanalysisof7prospectivetrialsofgemcitabinebased therapy with or without bevacizumab. Cancer 2014;120:1780–1786.
18. Kanz R, Vukovich T, Vormittag R et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011;9:57–63.
19. Pedersen LM, Sørensen PG. Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin’s lymphoma. Br J Haematol 2003;121:275–279.
20. Königsbrügge O, Lötsch F, Zielinski C et al. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res 2014;134: 44–49.